GHS-R1a is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-20. Numbers and descriptions here follow the published literature rather than marketing material.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Contains two non-natural residues |
| Molecular formula | C38H49N9O5 | Free base form |
| Molecular weight | 711.85 g/mol | Calculated from formula |
| Primary target | GHS-R1a ghrelin receptor | Agonist activity |
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
== Pharmaceutical use == As a synthetic drug, synephrine first appeared in Europe in the late 1920s, under the name of Sympatol. One of the earliest papers describing its pharmacological and toxicological properties was written by Lasch, who obtained it from the Viennese company Syngala. By 1930, Sympatol was referred to as a Boehringer product, while one of the first US Patents describing its preparation and use was assigned to Frederick Stearns & Co. in 1933. Despite the date of this patent, clinical and pharmacological research on synephrine obtained from Frederick Stearns & Co was being carried out in the US by 1930. Writing in 1931, Hartung reported that in 1930 the Council on Pharmacy and Chemistry of the American Medical Association had accepted synephrine for inclusion in its list of "New and Non-Official Remedies" as an agent for the treatment, by either oral or parenteral administration, "of attacks of hay fever, asthma, coughing, spasms of asthma and pertussis (whooping cough)." However, synephrine was dropped from the council's list in 1934, and its apparent re-advertising as a new drug by the Stearns company ten years later elicited a scathing comment from the Editors of the Journal of the American Medical Association. The third edition (1965) of Drill's Pharmacology in Medicine stated, with reservations, that synephrine was "advertised as an antihistaminic to be used in the treatment of the common cold...", under the trade name of "Synephrin Tartrate", and indicated that the dose was 100 mg, given intramuscularly, or subcutaneously.
Sorbitan monooleate (commercially: Span® 80; Croda International PLC) is a nonionic surfactant and emulsifier widely used in various industries, including food, pharmaceuticals, and cosmetics. It is a sorbitan ester produced by the esterification of sorbitan with oleic acid, resulting in a light yellow, viscous liquid that is insoluble in water but soluble in organic solvents.
=== Test to Stay === SHIELD Illinois piloted the "Test to Stay" program developed in cooperation with the Illinois Department of Public Health. Later endorsed by the CDC, Test to Stay allows unvaccinated students, faculty, and staff who have been exposed to SARS-CoV-2 positive individuals to remain in the classroom providing they wear a mask and test on days one, three, five, and seven following exposure. This program prevented the need to quarantine and exclude entire classes when one student in the group tests positive. During the pilot period alone, which only covered a population of 1,035 students and staff, "8,152 learning days were saved among close contacts."
Many proteins produced within the cell are secreted outside the cell to function as extracellular proteins. Extracellular proteins are exposed to a wide variety of conditions. To stabilize the 3D protein structure, covalent bonds are formed either within the protein or between the different polypeptide chains in the quaternary structure. The most prevalent type is a disulfide bond (also known as a disulfide bridge). A disulfide bond is formed between two cysteine amino acids using their side chain chemical groups containing a Sulphur atom, these chemical groups are known as thiol functional groups. Disulfide bonds act to stabilize the pre-existing structure of the protein. Disulfide bonds are formed in an oxidation reaction between two thiol groups and therefore, need an oxidizing environment to react. As a result, disulfide bonds are typically formed in the oxidizing environment of the endoplasmic reticulum catalyzed by enzymes called protein disulfide isomerases. Disulfide bonds are rarely formed in the cytoplasm as it is a reducing environment.
Sources: en.wikipedia.org
In 2010, the International Nomenclature Group for Constitutional Disorders of the Skeleton (INCDS) "freed" the Sillence types from molecular reference, acquiescing to their new clinical-first role in the wake of what was to them a "surprising" increase in the number of genetic causes of OI. Writing for the Annual Review of Genetics in 2012, Drs. Peter Byers and Shawna M. Pyott lamented how the expansion of the number of types to include genetic types has created a system that "grew like Topsy". They suggest that it may indeed be impossible to create a system which is useful for clinicians and which accurately describes the genetic cause of a person's OI, with attempts always prioritizing one use at the expense of the other.
=== Early uses === Animal glue has existed since ancient times, although its use was not widespread. Glue deriving from horse teeth can be dated back nearly 6000 years, but no written records from these times can prove that they were fully or extensively used. The first known written procedures for making animal glue were produced around 2000 BC. Between 1500 and 1000 BC, it was used for wood furnishings and mural paintings, and is found on the caskets of Egyptian pharaohs. Evidence for its use comes in the form of stone carvings depicting glue preparation and use. Egyptian records state that animal glue would be made by melting it over a fire and then applied with a brush. Ancient Greeks and Romans later used animal and fish glue to develop veneering and marquetry, the bonding of thin sections or layers of wood. Animal glue, known as taurokolla (ταυρόκολλα) in Greek and gluten taurinum in Latin, was made from the skins of bulls in antiquity. Broken pottery might also be repaired with the use of animal glues, filling the cracks to hide imperfections. About 906–618 BC, fish, ox horns and stag horns were used to produce adhesives and binders for pigments in China. Animal glues were employed as binders in paint media during the Tang dynasty. They were similarly used on the Terracotta Army figures. Records indicate that one of the essential components of lampblack ink was proteinaceous glue. Ox glue and stag-horn glues bound particles of pigments together, acting as a preservative by forming a film over the surface as the ink dried.
=== Osteoclast === Osteoclasts are very large multinucleate cells that are responsible for the breakdown of bones by the process of bone resorption. New bone is then formed by the osteoblasts. Bone is constantly remodeled by the resorption of osteoclasts and created by osteoblasts. Osteoclasts are large cells with multiple nuclei located on bone surfaces in what are called Howship's lacunae (or resorption pits). These lacunae are the result of surrounding bone tissue that has been reabsorbed. Because the osteoclasts are derived from a monocyte stem-cell lineage, they are equipped with phagocytic-like mechanisms similar to circulating macrophages. Osteoclasts mature and/or migrate to discrete bone surfaces. Upon arrival, active enzymes, such as tartrate-resistant acid phosphatase, are secreted against the mineral substrate. The reabsorption of bone by osteoclasts also plays a role in calcium homeostasis.
== Mechanical stress == Wounds under 2 millimeters generally do not scar, but larger wounds generally do scar. In 2011, it was found that mechanical stress can stimulate scarring and that stress shielding can reduce scarring in wounds. In 2021, it was found that using chemicals to manipulate fibroblasts to not sense mechanical stress brought scar-free healing. The scar-free healing also occurred when mechanical stress was blocked in a wound.
A thorium atom has 90 electrons, of which four are valence electrons. Four atomic orbitals are theoretically available for the valence electrons to occupy: 5f, 6d, 7s, and 7p. The 7p orbitals are not occupied in the ground state of thorium, however, due to being greatly destabilized. Despite thorium's position in the f-block of the periodic table, it has an anomalous [Rn]6d27s2 electron configuration in the ground state, as the 5f and 6d subshells in the early actinides are very close in energy, even more so than the 4f and 5d subshells of the lanthanides: thorium's 6d subshells are lower in energy than its 5f subshells, because its 5f subshells are not well-shielded by the filled 6s and 6p subshells and are destabilised. This is due to relativistic effects, which become stronger near the bottom of the periodic table, specifically the relativistic spin–orbit interaction. The closeness in energy levels of the 5f, 6d, and 7s energy levels of thorium results in thorium almost always losing all four valence electrons and occurring in its highest possible oxidation state of +4. This is different from its lanthanide congener cerium, in which +4 is also the highest possible state, but +3 plays an important role and is more stable. Thorium complexes in the trivalent and divalent oxidation states are known, however.
Sources: en.wikipedia.org
=== Economics === Following the US approval of Soliqua, Sanofi made a US$25 million milestone payment to Zealand. Zealand may receive additional payments up to US$110 million along with receiving royalties on global sales. Royalties paid to Zealand for Soliqua are based on a fixed low double-digit percentage of net sales. In January 2017, Sanofi announced that the wholesale acquisition cost (WAC) of a 3 ml pen of Soliqua is US$127. At the average dose used in clinical trials, this amounts to US$19.90 per day. According to Sanofi's Half-Year Financial Report, the net sales of Soliqua reached €9 million in the first six months of availability in the United States.
The US Navy has actively participated in the Saudi-led naval blockade of Houthi-controlled territory in Yemen, which humanitarian organizations argue has been the main contributing factor to the outbreak of famine in Yemen. The four-month long Battle of Aden (2015) occurred between 25 March 2015 and 22 July. According to a 2015 September report by Esquire magazine, the Houthis, once the outliers, are now one of the most stable and organised social and political movements in Yemen. The power vacuum created by Yemen's uncertain transitional period has drawn more supporters to the Houthis. Many of the formerly powerful parties, now disorganised with an unclear vision, have fallen out of favour with the public, making the Houthis—under their newly branded Ansar Allah name—all the more attractive. Houthi spokesperson Mohamed Abdel Salam stated that his group had spotted messages between the UAE and Saleh three months before his death. He told Al-Jazeera that there was communication between Saleh, UAE and a number of other countries such as Russia and Jordan through encrypted messages. The alliance between Saleh and the Houthi broke down in late 2017, with armed clashes occurring in Sanaa from 28 November. Saleh declared the split in a televised statement on 2 December, calling on his supporters to take back the country and expressed openness to a dialogue with the Saudi-led coalition. On 4 December 2017, Saleh's house in Sanaa was assaulted by fighters of the Houthi movement, according to residents. Saleh was killed by the Houthis on the same day.
== In platelets == The alpha granules in blood platelets contain growth factors PDGF, IGF-1, EGF, and TGF-β which begin healing of wounds by attracting and activating macrophages, fibroblasts, and endothelial cells.
=== 1988 === February 12, 1988 – Hostile rendezvous off coast of Crimea in Black Sea when the Soviet frigate Bezzavetnyy rammed the American missile cruiser USS Yorktown. February 20, 1988 – The regional soviet of Nagorno-Karabakh in Azerbaijan decides to be part of Armenia, but the Kremlin refuses to do it. The subsequent First Nagorno-Karabakh War would be the first of the internal conflicts in the Soviet Union that would become the post-Soviet separatist conflicts. August 8, 1988 – 8888 Uprising in Burma. August 17, 1988 – Pakistani president Muhammad Zia-ul-Haq dies. August 20, 1988 – End of Iran–Iraq War. September 17, 1988 – Summer Olympics in Seoul, South Korea; first time since 1976 that both Soviet Union and the United States participate; it is also the last Olympic Games for the Soviet Union and its satellite states. October 5, 1988 – Augusto Pinochet, dictator of Chile since September 1973, is defeated in a nationwide referendum. December 21, 1988 – Pan Am Flight 103 bombing.
==== Democratic Republic of the Congo and Rwanda ==== Rubio condemned the Rwandan-backed Goma offensive in the Democratic Republic of the Congo and called for an immediate ceasefire and respect for territorial integrity. In April, U.S. officials entered into talks with the DRC on a minerals deal after a proposal from Congolese president Félix Tshisekedi.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.
It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.
Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.